A recent large clinical trial offers promising news for early-stage breast cancer patients considering lymph node surgery options. The study found that omitting surgical lymph node removal during breast-conserving therapy did not negatively impact survival rates while reducing complications like lymphedema in patients with node-negative T1 or T2 breast cancer.
Key Findings
- Equivalent Survival Outcomes: Patients who skipped lymph node surgery showed nearly identical 5-year invasive disease-free survival rates (91.9%) compared to those who underwent sentinel lymph node biopsy (91.7%).
- Reduced Complications: The surgery-omission group experienced:
- 58% lower incidence of lymphedema
- Better arm mobility
- Less pain during arm/shoulder movement.
- Recurrence Differences: While axillary recurrence rates were slightly higher without surgery (1.0% vs. 0.3%), overall mortality was lower in the omission group (1.4% vs. 2.4%).
Study Details
- Involved 5,502 patients with early-stage (T1/T2), node-negative breast cancer
- Median follow-up of 6 years
- 90% of participants had small tumors (clinical T1 stage).
Implications for Patients
These results suggest many early-stage patients may safely avoid lymph node surgery without compromising survival, while experiencing better quality of life outcomes. The findings could lead to more personalized treatment plans, particularly for those concerned about lymphedema and mobility issues post-surgery. Patients should discuss these options with their care team to determine the best approach for their individual case.
More Reading
What is Lymphedema How is it Managed & Answers to Frequently Asked Questions
Treatment & Management of Breast Cancer
Join the Conversation on CancerConnect!
Reference:
Reimer T, Stachs A, Veselinovic K, et al. Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial. N Engl J Med. 2025 Mar 13;392(11):1051-1064.
